Serplulimab Plus Chemoradiotherapy vs Chemoradiotherapy as Adjuvant Treatment for Postoperative Cervical Cancer Patients With Multiple Risk Factors: A Randomized, Open-Label, Phase II Clinical Trial
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 134
- 试验地点
- 2
- 主要终点
- DFS
研究概览
简要总结
A Phase II Study of Serplulimab Plus Chemoradiotherapy as Adjuvant Treatment for Postoperative Cervical Cancer with Multiple Risk Factors
详细描述
This study is a randomized, controlled, open-label, Phase II clinical trial designed to enroll patients with at least two risk factors (risk factors: lymph node metastasis, positive parametrial or resection margins, lymphovascular space invasion, or deep stromal invasion) following radical surgery for cervical cancer. The study aims to evaluate the efficacy and safety of Serplulimab in combination with chemoradiotherapy compared to chemoradiotherapy alone as adjuvant treatment. Patients must be deemed suitable for cisplatin or carboplatin plus nab-paclitaxel treatment as determined by the investigator. The choice between carboplatin and cisplatin will be based on the clinical judgment of the investigator. Eligible patients will be randomized in a 1:1 ratio to one of the following treatment arms: patients receiving Serplulimab plus chemoradiotherapy as adjuvant treatment (experimental group) or patients receiving chemoradiotherapy alone as adjuvant treatment (control group). The study is expected to enroll 67 patients in each group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily participate in the clinical study: Fully understand and be informed about the study, and sign the informed consent form (ICF); willing to comply with and capable of completing all trial procedures.
- •Female aged ≥18 years and ≤65 years at the time of signing the ICF.
- •ECOG PS score of 0 or
- •Positive PD-L1 status (CPS ≥1).
- •Diagnosed with cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
- •FIGO (International Federation of Gynecology and Obstetrics) stage of IB1, IB2, IIA1, or IIA2, and patients judged by the investigator to benefit from radical surgery and/or adjuvant therapy.
- •Have undergone radical hysterectomy (Piver classification) and pelvic lymphadenectomy of type II or III.
- •Postoperative pathological examination confirms at least two adverse factors, which may include: Lymph node metastasis; Positive parametrial or positive resection margins; Lymphovascular space invasion; Deep stromal invasion;
- •Patients must meet the following hematological, renal, and liver function criteria: Absolute neutrophil count of at least 1.5 × 10⁹/L; Platelet count of at least 100 × 10⁹/L; Total bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels not exceeding 1.5 times the upper limit of normal; Creatinine levels not exceeding the upper limit of normal.
- •Female participants must have a negative serum pregnancy test within 14 days prior to treatment and agree to use effective contraception during the treatment period and for 6 months afterward; breastfeeding is prohibited during treatment.
- •Willing and able to comply with the trial and follow-up procedures.
排除标准
- •Patients with unresectable residual tumors.
- •Histologically confirmed diagnosis of cervical small cell carcinoma (neuroendocrine) or mucinous adenocarcinoma.
- •Patients who have previously received pelvic radiotherapy.
- •History of other untreated malignant tumors within the past 5 years, except for cured basal cell carcinoma of the skin or carcinoma in situ.
- •Presence of any active or known autoimmune disease.
- •History of inflammatory/autoimmune diseases requiring steroid treatment, or currently suffering from inflammatory/autoimmune diseases that require steroid treatment.
- •Diseases requiring systemic treatment with corticosteroids or other immunosuppressive agents within 14 days prior to randomization.
- •History of thromboembolic events (venous or arterial) occurring within 6 months prior to enrollment.
- •Poorly controlled clinical symptoms or conditions related to heart disease.
研究组 & 干预措施
Serplulimab plus chemoradiotherapy group
Serplulimab plus chemoradiotherapy group
干预措施: Chemotherapy (Drug)
Serplulimab plus chemoradiotherapy group
Serplulimab plus chemoradiotherapy group
干预措施: radiotherapy (Radiation)
chemoradiotherapy group
chemoradiotherapy group
干预措施: Chemotherapy (Drug)
chemoradiotherapy group
chemoradiotherapy group
干预措施: radiotherapy (Radiation)
Serplulimab plus chemoradiotherapy group
Serplulimab plus chemoradiotherapy group
干预措施: Serplulimab (Drug)
结局指标
主要结局
DFS
时间窗: through study completion, an average of 1 year
The time from the date of random assignment to the first occurrence of locoregional failure, DM, second primary tumor, or death from any cause.
次要结局
- OS(through study completion, an average of 1 year)
- RFS(through study completion, an average of 1 year)